Published by Josh White on 14th August 2025
(Sharecast News) - SkinBioTherapeutics said in an update on Thursday that revenue for the year ended 30 June were expected to rise almost fourfold to between £4.5m and £4.8m, driven by a full-year contribution from Dermatonics, eight months from Bio-Tech Solutions (BTS), and continued organic growth in AxisBiotix sales.